1. Home
  2. HYFM vs PCSA Comparison

HYFM vs PCSA Comparison

Compare HYFM & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hydrofarm Holdings Group Inc.

HYFM

Hydrofarm Holdings Group Inc.

HOLD

Current Price

$0.78

Market Cap

4.5M

Sector

Industrials

ML Signal

HOLD

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

BUY

Current Price

$1.69

Market Cap

4.2M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
HYFM
PCSA
Founded
1977
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
4.2M
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
HYFM
PCSA
Price
$0.78
$1.69
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
54.9K
★ 172.4K
Earning Date
11-11-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $134,252,000.00
$5,000.00
Revenue This Year
$54.93
N/A
Revenue Next Year
$5.31
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.50
$0.11
52 Week High
$3.20
$8.88

Technical Indicators

Market Signals
Indicator
HYFM
PCSA
Relative Strength Index (RSI) 38.94 46.51
Support Level $0.50 $1.04
Resistance Level $1.04 $2.33
Average True Range (ATR) 0.10 0.22
MACD -0.02 0.03
Stochastic Oscillator 18.78 65.92

Price Performance

Historical Comparison
HYFM
PCSA

About HYFM Hydrofarm Holdings Group Inc.

Hydrofarm Holdings Group Inc is an independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture (CEA), including grow lights, climate control solutions, grow media, nutrients, and other products. Hydroponics involves growing plants in soilless media, often using artificial lighting in controlled indoor or greenhouse environments. Its products are used to cultivate cannabis, flowers, fruits, vegetables, grains, and herbs, enabling control over key factors such as temperature, humidity, light, nutrients, and pH. Its product portfolio spans lighting, grow media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies. The United States generates maximum revenue.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

Share on Social Networks: